Project Grant 2537539
Award Date 7/15/26
Completion Date 12/31/26
Dollars Obligated $304K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92130, USA
Similar Awards
- Federal Project Grant Summary Endura Therapeutics Inc. received a $303,445 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) on May 15, 2025, with completion targeted for January 31, 2026. The award funds development of a next-generation sequencing-based platform designed to discover and screen small molecule drugs that target RNA. The primary deliverables include establishing...
- Federal Project Grant Award Summary Aleutian Therapeutics, Inc. received a $372,067 Project Grant award dated September 7, 2025, from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports the development of an immune-evasive stem cell line for Type 1 Diabetes (T1DM) regenerative therapy, with research to be conducted in California through August 31, 2026. This...
- Federal Grant Award Summary The National Science Foundation (NSF) awarded Piezo Therapeutics, Inc. a $304,742 Project Grant under the Technology, Innovation, and Partnerships program (CFDA 47.084) for a Phase I Small Business Innovation Research (SBIR) project running from October 1, 2025 through September 30, 2026. The awardee will develop and validate a novel intradermal vaccine delivery platform that eliminates the need for lipid nanoparticles (LNPs) by utilizing electroporation technology....
- Federal Grant Award Summary Biosettia Inc. received a $291,949 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 15, 2025, with completion targeted for August 31, 2026. The project delivers research services focused on developing and validating endogenous retrovirus (ERV) gag gene variants as biomarkers for Type 1 Diabetes (T1D)....
- Federal Grant Award Summary Singular Immune, Inc. received a $304,909 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships program (CFDA 47.084) effective July 1, 2026, with a completion date of June 30, 2027. The award funds development of a novel protein-based platform that enables Chimeric Antigen Receptor (CAR) generation in vivo without genetic modification of cells. Rather than inserting...
- Federal Grant Award Summary The National Science Foundation (NSF) awarded $304,450 to Lybra Bio Inc. under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) on June 15, 2025, for a Small Business Innovation Research (SBIR) Phase I project focused on developing a microneedle-based platform for treating autoimmune skin diseases. The project, with a completion date of January 31, 2026, seeks to advance a hydrogel-based microneedle patch technology that delivers therapeutics...
- Federal Grant Award Summary Nitro Biosciences Inc. received a $304,438 Small Business Technology Transfer (STTR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) effective October 1, 2025, with a completion date of September 30, 2026. The award supports development of an innovative vaccine platform utilizing engineered antigens containing chemically modified amino acids to overcome immune imprinting—a critical...
- Grant Award Summary SNC Therapeutics, Inc. received a $700,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective July 25, 2025 through July 24, 2026. The award funds development and research of rapamycin-loaded polymersomes (RPS), a tolerogenic nanotherapy designed to delay or prevent Type 1 Diabetes (T1D) onset in susceptible populations....
- This SBIR Phase I Project Grant, valued at $305,000.00 and awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop a novel class of peptide-based compounds capable of safely and effectively treating autoimmune and inflammatory disorders, including rare diseases affecting pediatric populations. The project will demonstrate the unique design of these compounds to modulate immune responses from pro- to...
- Federal Project Grant Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Miami School of Medicine's Office of Research Administration a $380,000 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025 through January 31, 2027. The award funds development and preclinical evaluation of PS03, a bifunctional RNA therapeutic designed to prevent Type 1 Diabetes (T1D) by inducing exhaustion in...